Syndesi Therapeutics
Description: Syndesi Therapeutics develops SV2A-modulating drugs for cognitive disorders in neurological conditions, licensed from UCB.
Country: Belgium
Based in: Louvain-la-neuve
Founded: 2018
Funding Stage: Series A/B
Tags: ['Biotechnology', 'Health Care', 'Technology']
ACCESS DIRECTORY
Details about how we process your information are available in our Privacy Policy.
